Hummingbird bioscience holdings limited

Index
Globenewswire

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

Globenewswire

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Globenewswire

Hummingbird Bioscience Licenses Novel Antibodies to Immunome

Globenewswire

Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024

Globenewswire

Hummingbird Bioscience Announces Key Leadership Appointments

Globenewswire

Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024